Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284276 | 0.98 | CYP19A1 (0.34) | CYP19A1MTNR1AMTNR1BEGFRKDM4E | |
| SCHEMBL3280349 | 0.95 | MTNR1A (0.34) | CYP19A1MTNR1AMTNR1B | |
| SCHEMBL3280705 | 0.87 | MTNR1A (0.38) | CYP19A1MTNR1AMTNR1BEGFRKDM4E | |
| SCHEMBL3280080 | 0.86 | KDM4E (0.33) | CYP19A1MTNR1AMTNR1BEGFRKDM4E | |
| SCHEMBL3279500 | 0.86 | CYP19A1 (0.33) | CYP19A1MTNR1AMTNR1BEGFR | |
| SCHEMBL8202811 | 0.85 | CYP19A1 (0.35) | CYP19A1MTNR1AMTNR1BEGFRMLKL | |
| SCHEMBL3280740 | 0.84 | MTNR1A (0.38) | CYP19A1MTNR1AMTNR1BEGFRKDM4E | |
| SCHEMBL8196011 | 0.83 | CYP19A1 (0.34) | CYP19A1MTNR1AMTNR1BEGFRMLKL | |
| SCHEMBL3279617 | 0.81 | MLKL (0.42) | CYP19A1EGFRKDM4EALDH1A1MLKL | |
| SCHEMBL3284735 | 0.81 | MTNR1A (0.37) | CYP19A1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705034-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705034-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705034-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080096953-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096953-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096953-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096953-A1 | Vinylogous acid derivatives | CMA1, TPSG1, GAA | CYP19A1 1050/4885MTNR1A 1303/4885MTNR1B 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.